Regenxbio (NSDQ:RGNX) has closed a license agreement with AbbVie (NYSE:ABBV) to develop RGX-314, a vascular endothelial growth factor inhibitor. The drug has been the focus of Phase 2 and Phase 3 trials exploring its potential in wet age-related macular degeneration (AMD) and diabetic retinopathy. AbbVie will make an upfront payment to Regenxbio of $370 million…

New macular degeneration treatments could offer superior durability to current anti-vascular endothelial growth factor therapy (anti-VEGF). But new drugs must have a similar safety profile to existing therapies to be competitive, according to a UBS briefing note.  The macular degeneration treatment landscape changed significantly in 2005 when FDA approved Macugen (pegaptanib sodium injection) from Pfizer (NYSE:PFE) to…